Shopping Cart 0
Cart Subtotal
USD 0

Aralez Pharmaceuticals Inc (ARLZ) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Aralez Pharmaceuticals Inc (Aralez Pharma) is a pharmaceutical company that develops and commercializes therapeutic drugs. The company offers products in the fields of cardiovascular diseases, pain management, dermatology, gastrointestinal, and other areas. Its pain management products include cambia, vimovo, treximet, durela, fiorinal and fiorinal C, among others. Aralez Pharma also offers non prescription products for women's health. Aralez Pharma's others products include blexten, moviprep, mutaflor, normacol, pegalax, proferrin, resultz, soriatane, and others. The company has operations in New Jersey, the US; and Dublin, Ireland. Aralez Pharma is headquartered in Mississauga, Ontario, Canada.

Aralez Pharmaceuticals Inc (ARLZ)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aralez Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aralez Pharma Acquires US Rights to Toprol-XL and Authorized Generic from AstraZeneca 13

Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 15

Venture Financing 16

Aralez Pharma Secures USD75 Million in Venture Debt Financing 16

Private Equity 17

Aralez Pharma to Sell its Toprol XL Franchise 17

Partnerships 18

Lannett Enters into Distribution Agreement with Aralez Pharma 18

Biohit Enters Into Distribution Agreement With Medical Futures 19

Merger 20

Pozen and Tribute Pharma Merges 20

Licensing Agreements 21

Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400 21

Equity Offering 22

Aralez Pharma Plans to Raise up to USD100 Million in Public Offering of Securities 22

Aralez Pharma Raises USD45 Million in Private Placement of Shares 23

Pozen Plans Public Offering of Shares for USD57.5 Million 25

Asset Transactions 26

Nuvo Pharma to Acquire Pharma Business from Aralez Pharma for USD110 Million 26

Acquisition 28

Tribute Pharma Acquires Medical Futures for USD20 Million 28

Aralez Pharmaceuticals Inc-Key Competitors 29

Aralez Pharmaceuticals Inc-Key Employees 30

Aralez Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 33

Strategy And Business Planning 33

Aug 13, 2018: Aralez Pharmaceuticals divests core businesses for USD 250m 33

May 08, 2018: Aralez Announces New Strategic Direction 34

Financial Announcements 35

May 08, 2018: Aralez Announces First Quarter 2018 Financial Results 35

Mar 13, 2018: Aralez Announces Fourth Quarter and Full-Year 2017 Financial Results 37

Nov 09, 2017: Aralez Announces Third Quarter 2017 Financial Results 40

Aug 09, 2017: Aralez Reports Second Quarter 2017 Financial Results 42

May 09, 2017: Aralez Reports First Quarter 2017 Financial Results 44

Mar 13, 2017: Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results 47

Corporate Communications 50

Nov 30, 2017: Aralez Announces Departure of Chief Financial Officer 50

Jun 07, 2017: Aralez Announces Board Member Resignation 51

Apr 05, 2017: Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program 52

Legal and Regulatory 53

Aug 20, 2018: Nuvo Pharmaceuticals announces extension of exclusivity period with Aralez and Deerfield 53

Product News 54

02/16/2018: Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet by Company's Subsidiary, Macoven Pharmaceuticals 54

02/03/2017: Pernix Therapeutics Provides Update on Arbitration 55

Product Approvals 56

Jan 09, 2017: Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aralez Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aralez Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aralez Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 11

Aralez Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Aralez Pharma Acquires US Rights to Toprol-XL and Authorized Generic from AstraZeneca 13

Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 15

Aralez Pharma Secures USD75 Million in Venture Debt Financing 16

Aralez Pharma to Sell its Toprol XL Franchise 17

Lannett Enters into Distribution Agreement with Aralez Pharma 18

Biohit Enters Into Distribution Agreement With Medical Futures 19

Pozen and Tribute Pharma Merges 20

Pozen Enters Into Licensing Agreement With Desitin Arzneimittel For MT 400 21

Aralez Pharma Plans to Raise up to USD100 Million in Public Offering of Securities 22

Aralez Pharma Raises USD45 Million in Private Placement of Shares 23

Pozen Plans Public Offering of Shares for USD57.5 Million 25

Nuvo Pharma to Acquire Pharma Business from Aralez Pharma for USD110 Million 26

Tribute Pharma Acquires Medical Futures for USD20 Million 28

Aralez Pharmaceuticals Inc, Key Competitors 29

Aralez Pharmaceuticals Inc, Key Employees 30

Aralez Pharmaceuticals Inc, Other Locations 31

Aralez Pharmaceuticals Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Aralez Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.